Vonvendi Approved By FDA, Bringing New Hope For Patients With Type A Hemophilia
About Vonvendi Vonvendi (vonicog alfa) is a recombinant von Willebrand factor (VWF) developed by Baxalta.…
Articles
Enlonstobart Injection Bringing New Hope To Patients With Rare Diseases
On October 15, 2023, the U.S. Food and Drug Administration (FDA) officially approved Enlonstobart Injection…
FDA Approves Besremi (Ropeginterferon Alfa-2b) For The Treatment Of True Erythrocytosis
The U.S. Food and Drug Administration (FDA) recently announced the approval of Besremi (generic name:…
Bimekizumab Bimzelx: Expanding Approvals Highlight Its Efficacy Across Multiple Indications
UCB has recently announced that its innovative therapy, Bimzelx (generic name: bimekizumab-bkzx), has received approval…
Nuwiq Demonstrates Low Inhibitor Development Rates In Previously Untreated Patients With Severe Hemophilia A
Lachen, Switzerland – Octapharma has announced that the final results from the NuProtect study on…
Benralizumab Injection: A Breakthrough In Asthma And EGPA Treatment
In the world of immunology and asthma management, Benralizumab Injection has emerged as a game-changer…
Gamifant Emapalumab LZSG: Targeted Therapy For Primary Hemophagocytic Lymphohistiocytosis
The trade name of emapalumab lzsg is Gamifant, which is an anti interferon gamma (IFN…
New Medication for Lung Cancer: Latest Treatments and Innovations You Need to Know
Introduction Lung cancer is one of the most common and serious types of cancer, but…
Padcev: A New Hope For Patients With Metastatic Urothelial Cancer
In the field of cancer treatment, targeted therapies and antibody-drug conjugates (ADCs) are emerging as…
FDA Approval Of CAR-T Therapy Carvykti Offers New Hope For Multiple Myeloma Patients
Recently, the U.S. Food and Drug Administration (FDA) officially approved Carvykti (Ciltacabtagene Autoleucel, or Cilta-cel),…